CalciMedica (CALC) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CalciMedica is the larger company by market cap ($9.0 million vs $8.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CALC | FBLG |
|---|---|---|
| Share price | $1.32 | $1.20 |
| Market cap | $8.98M | $8.35M |
| 1-day change | +1.15% | +8.28% |
| YTD return | -96.05% | — |
| 1-year return | -91.84% | — |
| EPS (TTM) | $-6.85 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.00 | $9.98 |
| 52-week low | $1.28 | $0.62 |
| Distance from 52-week high | -96.35% | -87.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +3702.28% | +941.75% |
| Average volume | 75.54K | 204.44K |
| Shares outstanding | 6.83M | 6.96M |
| Employees | 15 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CalciMedica
CALC stock →CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CALC vs FBLG FAQ
Which is bigger, CalciMedica or FibroBiologics?
CalciMedica (CALC) is larger, with a market capitalization of $8.98M compared with $8.35M for FibroBiologics (FBLG).
Are CalciMedica and FibroBiologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.